These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28065683)

  • 1. Cutaneous features of myotonic dystrophy types 1 and 2: Implication of premature aging and vitamin D homeostasis.
    Campione E; Botta A; Di Prete M; Rastelli E; Gibellini M; Petrucci A; Bernardini S; Novelli G; Bianchi L; Orlandi A; Massa R; Terracciano C
    Neuromuscul Disord; 2017 Feb; 27(2):163-169. PubMed ID: 28065683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysplastic nevi, cutaneous melanoma, and other skin neoplasms in patients with myotonic dystrophy type 1: a cross-sectional study.
    Zampetti A; Silvestri G; Manco S; Khamis K; Masciullo M; Bianchi ML; Damiani A; Santoro M; Linder D; Bewley A; Feliciani C
    J Am Acad Dermatol; 2015 Jan; 72(1):85-91. PubMed ID: 25440959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies.
    Passeri E; Bugiardini E; Sansone VA; Valaperta R; Costa E; Ambrosi B; Meola G; Corbetta S
    J Neurol Sci; 2013 Aug; 331(1-2):132-5. PubMed ID: 23809192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle pathology in myotonic dystrophy: light and electron microscopic investigation in eighteen patients.
    Nadaj-Pakleza A; Lusakowska A; Sułek-Piątkowska A; Krysa W; Rajkiewicz M; Kwieciński H; Kamińska A
    Folia Morphol (Warsz); 2011 May; 70(2):121-9. PubMed ID: 21630234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
    Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
    Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D deficiency in myotonic dystrophy type 1.
    Terracciano C; Rastelli E; Morello M; Celi M; Bucci E; Antonini G; Porzio O; Tarantino U; Zenobi R; Massa R
    J Neurol; 2013 Sep; 260(9):2330-4. PubMed ID: 23754696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectral domain optical coherence tomography findings in myotonic dystrophy.
    Abed E; D'Amico G; Rossi S; Perna A; Bianchi MLE; Silvestri G
    Neuromuscul Disord; 2020 Feb; 30(2):144-150. PubMed ID: 32005494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral nerve involvement in myotonic dystrophy type 2 - similar or different than in myotonic dystrophy type 1?
    Nojszewska M; Łusakowska A; Szmidt-Salkowska E; Gaweł M; Lipowska M; Sułek A; Krysa W; Rajkiewicz M; Seroka A; Kaczmarek K; Kamińska AM
    Neurol Neurochir Pol; 2015; 49(3):164-70. PubMed ID: 26048604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Neoplasms in Myotonic Dystrophy Type 1.
    Marcoval J; Olivé M; Bonfill-Ortí M; Martínez-Molina L; Talavera-Belmonte A
    Dermatology; 2016; 232(6):700-703. PubMed ID: 28249295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of calcium metabolism in type 1 myotonic dystrophy.
    Hlaing PM; Scott IA; Jackson RV
    Intern Med J; 2019 Nov; 49(11):1412-1417. PubMed ID: 30963668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.
    Arandel L; Polay Espinoza M; Matloka M; Bazinet A; De Dea Diniz D; Naouar N; Rau F; Jollet A; Edom-Vovard F; Mamchaoui K; Tarnopolsky M; Puymirat J; Battail C; Boland A; Deleuze JF; Mouly V; Klein AF; Furling D
    Dis Model Mech; 2017 Apr; 10(4):487-497. PubMed ID: 28188264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires.
    Romigi A; Albanese M; Placidi F; Izzi F; Liguori C; Marciani MG; Mercuri NB; Terracciano C; Vitrani G; Petrucci A; Di Gioia B; Massa R
    Eur J Neurol; 2014 Jun; 21(6):929-34. PubMed ID: 23837695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater cortical thinning and microstructural integrity loss in myotonic dystrophy type 1 compared to myotonic dystrophy type 2.
    Krieger B; Schneider-Gold C; Genç E; Güntürkün O; Prehn C; Bellenberg B; Lukas C
    J Neurol; 2024 Aug; 271(8):5525-5540. PubMed ID: 38896263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
    Cho DH; Tapscott SJ
    Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland.
    Suominen T; Bachinski LL; Auvinen S; Hackman P; Baggerly KA; Angelini C; Peltonen L; Krahe R; Udd B
    Eur J Hum Genet; 2011 Jul; 19(7):776-82. PubMed ID: 21364698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy.
    Logigian EL; Ciafaloni E; Quinn LC; Dilek N; Pandya S; Moxley RT; Thornton CA
    Muscle Nerve; 2007 Apr; 35(4):479-85. PubMed ID: 17230537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body composition analysis in patients with myotonic dystrophy types 1 and 2.
    Peric S; Bozovic I; Nisic T; Banovic M; Vujnic M; Svabic T; Pesovic J; Brankovic M; Basta I; Jankovic M; Savic-Pavicevic D; Rakocevic-Stojanovic V
    Neurol Sci; 2019 May; 40(5):1035-1040. PubMed ID: 30790082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.
    Fitzgerald BP; Conn KM; Smith J; Walker A; Parkhill AL; Hilbert JE; Luebbe EA; Moxley RT
    J Neurol; 2016 Dec; 263(12):2528-2537. PubMed ID: 27734165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and type of cancers in myotonic dystrophy: A retrospective cross-sectional study.
    D'Ambrosio ES; Chuang K; David WS; Amato AA; Gonzalez-Perez P
    Muscle Nerve; 2023 Aug; 68(2):142-148. PubMed ID: 36790141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2.
    Tieleman AA; Knoop H; van de Logt AE; Bleijenberg G; van Engelen BG; Overeem S
    J Neurol Neurosurg Psychiatry; 2010 Sep; 81(9):963-7. PubMed ID: 20798200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.